Interchangeability, Meetings And Access Among BsUFA III Priorities

Stakeholders Offer Specific Recommendations On US Biosimilar User Fee Program

Industry stakeholders have offered their views on key priorities for the BsUFA biosimilars user-fee program ahead of its reauthorization.

recommendations
AAM, Biocon and Sandoz offer BsUFA III recommendations • Source: Shutterstock

Interchangeability, early meetings, review timelines and access are among the key priorities that have been set out by US biosimilars industry stakeholders as the Biosimilar User Fee Act approaches its second reauthorization.

As the US Food and Drug Administration aims to set priorities for the reauthorization of BsUFA for fiscal years 2023...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.